 "US FDA approves Glenmark Pharma's drug for overactive bladder")
The company has been granted tentative approval by the United States Food and Drug Administration (US FDA) for Solifenacin Succinate tablets, 5 mg and 10 mg, Glenmark Pharmaceuticals said in a BSE filing.
The company's products are the generic version of Vesicare tablets, 5 mg and 10 mg of Astellas Pharma US Inc.
Also Read
According to IMS Health April 2017 sales data, the market for Vesicare tablets, 5 mg and 10 mg, saw annual sales of approximately $1.1 billion.
Glenmark's current portfolio consists of 117 products authorised for distribution in the US marketplace, the company said, adding that it has 68 ANDAs pending approval with the US FDA.
The scrip was trading 0.79 per cent higher at Rs 633.65 on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%